SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Prosus N.V. (PROSY) trades at a trailing P/E of 9.7, forward P/E of 12.8. Trailing earnings yield is 10.36%, forward earnings yield 7.79%. PEG 0.09 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (9.7); PEG ≤ 1.0 — Peter Lynch undervalued (0.09); earnings yield beats bond yields (10.36%).
- PEG Ratio 0.09 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 10.36% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 86/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PROSY
Valuation Multiples
P/E (TTM)9.7
Forward P/E12.8
PEG Ratio0.09
Forward PEG0.49
P/B Ratio0.00
P/S Ratio19.37
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.03
Forward EPS (Est.)$0.77
Book Value / Share$0.00
Revenue / Share$0.51
FCF / Share$0.00
Yields & Fair Value
Earnings Yield10.36%
Forward Earnings Yield7.79%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$0.04 |
$1.84B |
$2.61B |
142% |
| 2018 |
$0.18 |
$2.3B |
$11.49B |
498.7% |
| 2019 |
$0.04 |
$2.66B |
$3.58B |
134.9% |
| 2020 |
$0.04 |
$3.33B |
$3.77B |
113.2% |
| 2021 |
$0.08 |
$5.12B |
$7.45B |
145.6% |
| 2022 |
$0.23 |
$5.22B |
$18.73B |
358.9% |
| 2023 |
$0.14 |
$5.77B |
$10.11B |
175.4% |
| 2024 |
$0.51 |
$5.47B |
$6.61B |
120.8% |
| 2025 |
$1.03 |
$6.17B |
$12.37B |
200.4% |
